Lipoprotein lipase gene therapy - Avigen
Latest Information Update: 07 Sep 2005
At a glance
- Originator Avigen
- Class Gene therapies
- Mechanism of Action Lipoprotein lipase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypertriglyceridaemia
Most Recent Events
- 27 Jun 2005 Discontinued - Preclinical for Hypertriglyceridaemia in USA (IM)
- 18 Mar 1998 New profile
- 18 Mar 1998 Preclinical development for Hypertriglyceridaemia in USA (IM)